Background-Although numerous single-nucleotide polymorphisms (SNPs) in chromosome 9p21 have been associated with coronary artery disease (CAD) and incident myocardial infarction (MI) in whites, there are limited and conflicting reports on the association of this locus with prognosis in whites with existing CAD and no reports in blacks or Hispanics. We investigated the hypothesis that 9p21 polymorphisms are associated with increased risk for adverse cardiovascular outcomes in patients with documented CAD.
coronary artery disease (CAD) arises from a combination of genetic and environmental factors. Four genome-wide association studies in 2007 independently identified the chromosomal locus 9p21 as being a susceptibility locus for CAD or myocardial infarction (MI) among whites. [1] [2] [3] [4] Subsequent studies have replicated these findings and found association of this locus with also stroke and aortic aneurysm in Northern European and North American white populations 1, [5] [6] [7] [8] [9] and East Asian populations. 10, 11 A recent meta-anal-ysis included 22 reports with 47 distinct data sets and found a statistically significant association between 9p21 SNPs and risk for coronary heart disease, CAD, or MI that varied by age at disease onset, with odds ratios (ORs) higher at younger ages (Ͻ55 years) of disease onset. 12 The chromosome 9p21 represents the most replicated locus for CAD and MI in whites to date, with rs1333049 being the strongest single-nucleotide polymorphism (SNP), tagging multiple SNPs in high linkage disequilibrium (LD) in this region. The risk allele is common, with an allele frequency of almost 50%, and is associated with a 20% to 30% increased risk per risk allele. Although the association of the 9p21 region with risk for developing CAD is well defined, the association of this region with adverse outcomes in patients with established CAD is unclear. Four recent studies reported conflicting results about the association of 9p21 SNPs with clinical outcomes in white patients with existing CAD. One reported that the CAD/MI risk allele [C] of rs1333049 was associated with higher risk for recurrent MI and mortality after acute coronary syndromes (ACS), 13 2 found no association with subsequent mortality in patients with CAD, 14, 15 and 1 found a trend for decreased risk for incident MI per C allele in patients with CAD. 16 We were unable to identify reports on such associations with prognosis in individuals of African descent or Hispanic ethnicity.
Clinical Perspective on p 178
We sought to determine whether the risk alleles of the 9p21 SNPs, previously associated with increased risk of incident CAD and MI, are also associated with increased risk for adverse cardiovascular (CV) outcomes, such as death, nonfatal MI, or nonfatal stroke, among elderly hypertensive patients with established stable CAD. We used data from the International Verapamil SR Trandolapril Study (INVEST) clinical trial, which included a diverse population with well-controlled blood pressure, and we tested this hypothesis in whites, blacks, and Hispanics. We sought to replicate our findings in a distinct cohort of patients with ACS from the Investigation of Outcomes From Acute Coronary Syndromes Study (INFORM). This question is particularly important given that the exact molecular mechanism by which the chromosome 9p21 region increases risk of incident CAD is not yet fully understood (and may have different implications in different patient populations), and currently, there is no direct way to pharmacologically modulate the risk imposed by the chromosome 9p21 locus. Further, direct-to-consumer genetics companies are offering genotyping of this locus to patients, so an understanding of how well the previously noted associations apply to different patient populations is important.
Methods

INVEST-Genetic Substudy Participants
INVEST compared adverse CV outcomes in 22 576 hypertensive patients with CAD randomized to 2 different antihypertensive treatment strategies. 17, 18 Details of the methods and main outcomes were previously reported. 17, 18 Briefly, patients with CAD and essential hypertension requiring drug therapy who were aged Ն50 years were eligible. Patients were randomly assigned to a verapamil SR-or an atenolol-based treatment strategy. Details on addition of study drugs and dose titration are published elsewhere. 17, 18 The INVEST Genetic Substudy (INVEST-GENES) cohort consisted of 5979 patients from 213 sites in the United States who provided genomic DNA samples and additional written informed consent for genetic studies.
INVEST-GENES Case-Control Samples
The INVEST-GENES case-control sample, a subset of INVEST-GENES cohort, included all 304 patients (cases) who experienced a primary outcome event during the trial (first occurrence of all-cause death, nonfatal MI, or nonfatal stroke) and frequency-matched controls (who did not experience death, MI, or stroke) matched on age (decades), sex, and race/ethnicity (defined as self-identified race/ethnicity as recorded by the physician).
Outcomes
The primary outcome was the first occurrence of all-cause mortality, nonfatal MI, or nonfatal stroke. Secondary outcomes were the individual components of the primary outcome. Events were adjudicated by an independent committee that was blinded to treatment strategy. 17 
INFORM Participants (Replication Cohort)
INFORM is a prospective cohort study of patients with ACS admitted to 2 Kansas City, Missouri, medical centers between March 2001 and October 2002. 19 Standard definitions were used in the diagnosis of ACS in patients with either MI or unstable angina. Patients with MI were identified by an elevated troponin value in the setting of symptoms or electrocardiographic changes (both STsegment elevation and non-ST-segment elevation changes) consistent with an MI. Unstable angina was diagnosed if the patient had a negative troponin blood test and any 1 of the following: new-onset (Ͻ2 months) angina of at least class III of the Canadian Cardiovascular Society Classification, prolonged (Ͼ20 minutes) rest angina, recent (Ͻ2 months) worsening of angina, or angina that occurred within 2 weeks of an MI. 19 
Outcomes
The primary end point of INFORM was the composite of first occurrence of all-cause mortality or cardiac rehospitalization. The secondary outcomes were the individual components of the primary outcomes. Cardiac rehospitalization was assessed by patient interview and included hospitalization for MI, heart failure, chest pain, planned percutaneous coronary intervention, or planned coronary artery bypass graft surgery. Mortality assessment was made using the Social Security Administration Death Master File (http://www.ntis. gov/products/ssa-dmf.asp).
Genotyping
Genotyping details are shown in the online-only Data Supplement. Briefly, we obtained genotype data for 153 SNPs in the 9p21 region on the INVEST-GENES case-control samples from the gene-centric human CVD 50K SNP array (Illumina). We also genotyped rs2383207 and rs10757278 in the INVEST-GENES cohort and rs2383207, rs10757278, rs7049105, and rs2157719 in the INFORM cohort.
Statistical Analyses
To minimize the potential for population stratification in our racially and ethnically diverse population in INVEST, all analyses were conducted separately by race/ethnicity and adjusted for the first 2 eigenvectors in the principal component analysis performed on a set of LD-pruned SNPs using EIGENSTRAT software. 20 The analysis in white individuals was considered primary, and analyses in the Hispanic and black individuals were considered secondary given that these groups were underpowered and we did not have a replication cohort for the Hispanic group. Hardy-Weinberg equilibrium was tested for each racial/ethnic group using 2 analysis with 1 degree of freedom. LD (r 2 ) among the SNPs in each racial/ethnic group was estimated using Haploview. 21 Haplotypes were constructed for each race/ethnicity group using PHASE version 2.1. 22 For the INVEST-GENES case-control samples, the association of the 153 SNPs in the chromosome 9p21 region and primary outcome was assessed using logistic regression within each race/ethnicity group with and without adjusting for age, sex, principal component analysis (first 2 eigenvectors), treatment strategy, diabetes, history of MI and heart failure, average on-treatment blood pressure, and smoking. For all genotypes, the risk allele (defined as published risk allele or minor allele for those not published before) homozygotes were coded as 2, heterozygotes as 1, and nonrisk allele homozygotes as 0. ORs per risk allele and 95% CIs were calculated. To be considered statistically significant for this analysis, the P values for single SNPs needed to be Ͻ0.00032 (0.05/155). Case-control association analysis of these SNPs were performed in PLINK. 23 For haplotype analysis, the P values needed to be Ͻ0.0056 (0.05/9, where 9 is the number of haplotypes with frequency Ͼ1% in whites) to be considered statistically significant.
For the SNPs tested in the INVEST-GENES and INFORM cohorts, Cox proportional hazard modeling was performed to assess the association of the SNPs and the time to adverse CV outcomes, adjusting for prespecified variables that were shown to be associated with outcomes. Unadjusted hazard ratios (HRs) also were reported. In INVEST, models were adjusted for age, sex, treatment strategy, diabetes, history of heart failure and history of MI, average on-treatment blood pressure, hyperlipidemia, and smoking. In INFORM, models were adjusted for age, sex, ACS type, revascularization strategy (medical management, percutaneous coronary intervention, or coronary artery bypass graft surgery), hypertension, diabetes, history of heart failure, hyperlipidemia, and history of MI. The HRs represent risk per risk allele (as defined as previous CAD risk allele or minor allele if not published previously). The assumption of the proportional hazards was tested in each Cox regression model using Schoenfeld residuals. 24 We defined statistical significance as PϽ0.0125 for replication in INFORM along with point estimates in the same direction as in INVEST-GENES. 23
Results
INVEST-GENES Participant Baseline Characteristics
The INVEST-GENES cohort consisted of an ethnically diverse (40% white, 47% Hispanic, and 12.5% black) elderly population (mean age, 66Ϯ10 years) of patients with hypertension and documented CAD (23.2% with history of MI, 74.4% with classic angina pectoris). The average follow-up period was 2.8 years, with a total of 16 946 person-years of follow-up. In INVEST-GENES, 5907 (98.8%) patients had genotype data on at least 1 9p21 SNP. The baseline characteristics and medical history of these patients are shown in online-only Data Supplement Table 1 .
INVEST-GENES case-control samples (nϭ1460) included 858 (58.8%) white, 212 (14.5%) black, and 390 (26.7%) Hispanic elderly patients (mean age, 70.5Ϯ9.3 years) with hypertension and documented CAD (54% with history of MI, 64% with classic angina pectoris). There were significant differences in baseline demographics (eg, age, sex, body mass index, baseline blood pressure) and medical history (eg, percentage of patients with history of MI, heart failure, angina, diabetes) among white, black, and Hispanic patients (all PϽ0.0001).
9p21 SNP Association With INVEST-GENES Primary Outcome
We analyzed the association of all 153 SNPs in 9p21 region on the CVD SNP array with the INVEST primary outcome in the case-control samples (nϭ1460) and 2 SNPs (rs2383207 and rs10757278) in the entire INVEST-GENES cohort (nϭ5979). The 8 SNPs with significant association (PϽ0.00032 in whites) with the primary outcome are shown in Table 1 . None of these SNPs reached statistical significance in blacks or Hispanics; 2 SNPs in blacks and 1 in Hispanics trended toward significance (PϽ0.01) ( Table 1 ). The 6 SNPs previously reported to be associated with risk for developing CAD/MI in whites (rs10757274, rs2891168, rs2383206, rs2383207, rs10757278, and rs1333049) are shown in Table 1 (highlighted in boldface type) even though they did not meet the threshold of statistical significance used for the novel SNPs from the CVD SNP array in INVEST-GENES white participants. The genotype and allele frequencies of these SNPs are shown in online-only Data Supplement Table 3 .
LD and Haplotype Analysis of the 9p21 SNPs
We explored the LD among the 16 top SNPs described previously, including the 6 most reported 9p21 SNPs from the literature in Haploview and constructed haplotypes for each race/ethnic group. In white patients, these SNPs formed 2 distinct LD blocks, with the 8 strongest SNPs in this analysis in 1 block (block 1) and the 6 most reported SNPs in another block (block 2) ( Figure 1 ). As expected, the LD of the SNPs in each block was the strongest in whites, weakest in blacks, and intermediate in Hispanics.
In LD block 1, which consists of the 8 strongest SNPs, the 2 most frequent haplotypes in whites (Hap1 and Hap2) accounted for 82% of the white chromosomes, 73% of the Hispanic chromosomes, and 34% of the black chromosomes ( Figure 2A ). Hap1 of block 1 was associated with 40% better prognosis (lower risk for primary outcome) in whites (OR, 0.60; 95% CI, 0.47 to 0.77; Pϭ4.0ϫ10 Ϫ5 ) but not in blacks (OR, 0.81; 95% CI, 0.46 to 1.43; Pϭ0.475) or Hispanics (OR, 0.80; 95% CI, 0.55 to 1.17; Pϭ0. 25) . The second most frequent haplotype, Hap2, with complementary alleles to Hap1, was associated with worse prognosis (higher risk for primary outcome) among both whites (OR, 1.52; 95% CI, 1.20 to 1.93; Pϭ0.0006) and blacks (OR, 4.11; 95% CI, 1.55 to 10.88; Pϭ0.004) but not among Hispanics (OR, 0.98; 95% CI, 0.59 to 1.62; Pϭ0.93) (Figure 2A ).
In LD block 2, containing the 6 9p21 SNPs from the literature (rs2383206, rs2383207, rs10757278, rs1333049, rs10757274, and rs2891168), the 2 most frequent haplotypes (Hap1, GGGGGC; Hap2, AAAAAG) accounted for Ͼ91% of the white chromosomes, 71% of the Hispanic chromosomes, and 36% of the black chromosomes ( Figure  2B ). In white patients, block 2 Hap1 (containing risk alleles from the incident CAD/MI literature) was associated with a trend toward better prognosis (OR, 0.72; 95% CI, 0.57 to 0.92; Pϭ0.0085), whereas block 2 Hap2, with complementary alleles, trended toward worse prognosis (OR, 1.32; 95% CI, 1.04 to 1.67; Pϭ0.024). There was no evidence of such associations in blacks and Hispanics. We did not observe any differences in 9p21 associations between randomized treatment strategies (ie, atenolol versus verapamil) (treatmentϫSNP interaction Pϭ0.86).
Associations of rs2383207 and rs10757278 With Primary and Secondary Outcomes in INVEST-GENES Cohort
As described in the online-only Data Supplement Methods, the 2 most widely reported SNPs from the body of literature surrounding the chromosome 9p21 region and CAD/MI risk association, rs2383207 and rs10757278, were not captured on the CVD SNP array and were genotyped separately in the entire INVEST-GENES cohort. The event rates and unadjusted and adjusted HRs for the primary outcome in each race/ethnic group of rs2383207 and rs10757278 are shown in Table 2 . Neither of these SNPs reached statistical significance in any of the 3 racial/ethnic groups studied when the association with INVEST primary outcome was tested. The HRs for prognosis among the risk alleles were directionally opposite compared with the published HRs for CAD/MI risk in whites for both SNPs, with the well-documented G alleles showing a trend for protection against adverse CV outcome. The adjusted HRs for rs2383207 and rs10757278 G alleles were 0.75 (95% CI, 0.60 to 0.93; Pϭ0.0083) and 0.81 (95% CI, 0.66 to 1.0; Pϭ0.05), respectively. (Table 3 ). The association of rs10757278 also showed the same trend in the INFORM white participants, with the G allele of this SNP (Table 3) , although they did not achieve statistical significance. 
Replication of Associations in INFORM
Discussion
The chromosome 9p21 region is the most replicated risk locus for CAD. However, whether this chromosomal region also is associated with prognosis in those with existing CAD is not well understood. Using 2 similar, but independent cohorts, our data suggest that the 9p21 alleles that were previously associated with higher risk for development of CAD/MI are not associated with higher risk for long-term adverse outcomes among patients with established CAD. Instead, in both of our populations, the previously identified CAD/MI risk alleles trended toward protection from adverse outcomes among patients with established CAD. A less commonly reported LD block (block 1) was more strongly associated with prognosis in INVEST among both whites and blacks than the more commonly reported LD block (block 2 , the direction of association in INFORM was consistent with those in INVEST-GENES, and P values trended toward significance. Thus, both study populations strongly suggest that the traditional risk alleles for CAD are not associated with additional prognostic risk in patients with established CAD. In fact, the data suggest that these alleles may be protective, as they relate to long-term adverse CV outcomes.
Previous reports may provide some insight into why we did not observe an association between chromosome 9p21 and higher risk for adverse outcomes among patients with established CAD and, if anything, saw results in the opposite direction from the widely replicated associations with CAD/MI risk. First is the study by Horne et al 16 in which they also saw no association with MI compared to patients with CAD/no MI. They confirmed these findings in 7 European case-control sets, again showing no association with MI compared to patients with CAD/no MI. In fact, the ORs in this study were all Ͻ1 (OR, 0.9; 95% CI, 0.81 to 0.99), which is consistent with our finding in the present study. Second is a recent study by Dandona et al 15 in which investigators found that rs1333049 [C] of the chromosome 9p21 region was associated with greater atherosclerotic burden rather than with the likelihood for plaque rupture, with no association with MI when disease severity was accounted for. Unfortunately, in the present study, we do not have angiographic data in all patients to evaluate the association between disease severity and chromosome 9p21. Third is a study by Muehlschlegel and colleagues 25 who reported that the major allele of 9p21 SNP rs10116277 (in LD with rs1333049; r 2 ϭ0.9 based on Hapmap whites) was associated with lower risk for all-cause mortality within 5 years after coronary artery bypass graft surgery. Finally, a recent study by Reilly and colleagues 26 demonstrated that the SNPs predisposing to MI in patients with coronary atherosclerosis are distinct from those that associated with the development of coronary atherosclerosis, with a 9p21 SNP being an example. We found a haplotype in a less commonly reported LD block (block 1) to be associated with better prognosis (lower risk for CV outcome) in INVEST among whites (OR, 0.60; 95% CI, 0.47 to 0.77; Pϭ4.0ϫ10 Ϫ5 ) but not in blacks(OR, 0.81; 95% CI, 0.46 to 1.43; Pϭ0.475) or Hispanics (OR, 0.80; 95% CI, 0.55 to 1.17; Pϭ0.25) . We also found the complementary haplotype in this block that was associated with worse prognosis (higher risk for CV outcome) among both whites (OR, 1.52; 95% CI, 1.20 to 1.93; Pϭ0.0006) and blacks (OR, 4.11; 95% CI, 1.55 to 10.88; Pϭ0.004) but not Hispanics (OR, 0.98; 95% CI, 0.59 to 1.62; Pϭ0.93). Unfortunately, none of the previously mentioned studies evaluated any SNPs in LD block 1, which would be of interest to see whether the associations we observed in the present study hold true. 15, 16, 25 Given that our associations with prognosis were in the opposite direction of the association with disease risk and that many of the alleles in this region have frequencies very close to 50% in whites, it is important to ensure proper coding of the alleles. This fact becomes especially critical given that the actual causal allele has not yet been agreed on and a given allele has even been reported to both increase and decrease regulatory activity in the region. [27] [28] [29] [30] Taken together, we are left with a dangerous scenario whereby "risk" alleles may be misreported because of slight differences in frequency and LD patterns. To further complicate the matter, many of the SNPs involve complementary alleles (eg, G/C and A/T SNPs such as rs1333049 and rs7044859), making allele calling even more problematic. Given that INVEST-GENES is ethnically diverse and that the minor allele frequencies in blacks and Hispanics do not approach 50% as they do in whites (eg, 13% and 32% in blacks and Hispanics, respectively, versus 45% in whites for rs2393207) (online-only Data Supplement Table 3 ), it was far easier for us to identify errors in genotype calling generated from strand issues than it would be for groups with large European populations. Difficulties in precisely and reproducibly identifying genotypes, particularly when there is a similar prevalence of high-and low-risk alleles in a population, is an important issue for investigators and clinicians particularly because direct-toconsumer genotyping companies are already giving patients an estimate of their heart disease risk based on the chromosome 9p21 SNP genotyping results.
Table 2. Risk for INVEST Primary Outcome and rs2383207 and rs10757278
To our knowledge, the present study is the first to report the analysis of the 9p21 locus with adverse outcomes in black and Hispanic patients with hypertension and CAD, although underpowered and hypothesis generating in nature in these groups. Given that the LD is much lower in blacks than in whites, evaluating the same SNP associations across different race/ ethnicity groups may allow us to identify functionally important SNPs. Indeed, we found a haplotype that was associated with risk for adverse outcome in both whites and blacks. Interestingly, despite having intermediate LD between whites and blacks, we observed no SNPs associated with adverse outcomes in Hispanic individuals (mostly those from Puerto Rico). It is possible that environmental factors may play a larger role in CV outcomes in these Hispanic individuals or that there are relative differences in the penetrance of genetic factors.
Limitations
The present study has some limitations that are worth noting. First, the sample size of the replication cohort of INFORM participants was relatively small compared with INVEST-GENES white participants; therefore, we cannot conclude whether lack of replication of block 1 SNPs in INFORM white participants was due to suboptimal power or truenegative associations. The trends toward significance and consistency of point estimates suggest power may have been an issue. Second, the INVEST and INFORM populations had some important phenotypic differences between them (eg, patients with stable CAD versus ACS) that may have contributed to the lack of replication of the block 1 associations. Third, our analyses in blacks in both INVEST and INFORM are underpowered and, therefore, are hypothesis generating in nature.
Conclusion
The well-documented chromosome 9p21 SNPs associated with higher risk for incident CAD/MI did not appear to be associated with increased risk for adverse outcomes among patients with established CAD. In fact, our findings suggest trends toward protection from those SNPs widely published for association with incident CAD/MI risk. Several other studies also noted no association between 9p21 and prognosis 14, 15 or association in the opposite direction. 16, 25 Whether the 9p21 haplotype in a different LD block (LD block 1) than the most often reported block is associated with prognosis should be investigated further in populations with established CAD. Caution is warranted when interpreting direct-toconsumer genetics tests of this locus because the risk allele may differ depending on the patient population. As more becomes understood regarding the mechanisms by which these SNPs modulate CAD pathogenesis, we will be better able to assess how their effects may differ in disease initiation versus progression.
CLINICAL PERSPECTIVE
To date, the chromosome 9p21region is the best-replicated independent genetic risk factor for development of coronary artery disease (CAD), usually as incident myocardial infarction, among whites. However, whether this genetic marker is a predictor of adverse outcomes among patients with established CAD is unclear. Given that our ability to predict which individuals will develop adverse outcomes is limited, and direct-to-consumer genetics companies are offering genotyping of this locus to patients, an understanding of how well previously noted associations apply to different patient populations is important. Accordingly, we investigated whether alleles of 9p21 single-nucleotide polymorphisms (SNPs) previously associated with increased risk for incident CAD also were associated with increased risk for adverse cardiovascular outcomes among patients with previously documented CAD. We used data from 2 cohorts: 1 enrolled with chronic stable CAD (International Verapamil SR Trandolapril Study) and 1 enrolled at the time of an acute coronary syndrome (Investigation of Outcomes From Acute Coronary Syndromes Study). Both cohorts were followed for at least 2 years for cardiovascular outcomes. We found the 9p21 SNPs previously associated with higher risk for incident CAD/myocardial infarction were not associated with long-term outcomes among patients with established CAD. Several other studies also have noted no association between 9p21 and prognosis, and some suggest a protective effect associated with these SNPs among patients with established CAD. Caution, therefore, is warranted when interpreting genetic tests of the 9p21 locus because the risk associated with an allele may differ depending on the patient population.
